Get the Stockscreener App
12.06
1.77%
0.21
After Hours:
12.07
0.010
+0.08%
Bausch Lomb Corp stock is traded at $12.06, with a volume of 845.19K.
It is up +1.77% in the last 24 hours and down -21.69% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$11.85
Open:
$11.82
24h Volume:
845.19K
Relative Volume:
1.17
Market Cap:
$4.33B
Revenue:
$4.79B
Net Income/Loss:
$-317.00M
P/E Ratio:
-13.25
EPS:
-0.91
Net Cash Flow:
$-59.00M
1W Performance:
+6.54%
1M Performance:
-21.69%
6M Performance:
-42.38%
1Y Performance:
-15.72%
1-Day Range:
$11.72
$12.12
1-Week Range:
$10.96
$12.38
52-Week Range:
$10.46
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
12.06 | 4.33B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo Finance
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Bausch + Lomb Gears Up For Q1 2025 Results Announcement - Finimize
WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty - Baystreet.ca
Why Bausch + Lomb (BLCO) Shares Are Plunging Today - Yahoo Finance
Bausch + Lomb recalls some of its implantable eye lenses - Reuters
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb shares fall on voluntary recall By Investing.com - Investing.com Canada
Bausch + Lomb to Announce Q1 2025 Financial Results - TipRanks
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30 - Yahoo Finance
Bausch & Lomb Says Amcor Must Pay For Botched Bottles - Law360
Bausch + Lomb credit rating upgraded to ’B’ at S&P, parent company outlook developing - Investing.com India
Stocks In Play: Bausch + Lomb Corporation - Barchart
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States - BioSpace
Contact Lenses Market Forecast Report and Company Analysis 2025-2033 Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya, EssilorLuxottica, Menicon, and Seed - Yahoo Finance
U.S. Contact Lenses Market Size and Share Analysis 2025-2033, Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya Corporation & More - Yahoo Finance
Judge Advises Affirming Bausch & Lomb Vitamin Patents' Validity - Bloomberg Law
Bausch + Lomb's SWOT analysis: eye health stock sees growth amid challenges - Investing.com
Morgan Stanley cuts Bausch & Lomb stock target to $18 from $19 - Investing.com
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts - Defense World
Bank of America Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $17.00 - Defense World
Bausch & Lomb stock target cut to $20 at H.C. Wainwright - Investing.com UK
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb Begins to Reap Fruits of Innovation; Broad-Based Growth Fuels Our Long-Term Outlook - Morningstar
Bausch + Lomb Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance - BioSpace
Bausch + Lomb Corp. Announces FY25 Revenue Within View - Nasdaq
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results - TradingView
Bausch + Lomb Posts Q4 Revenue of US$1.28 Billion -February 19, 2025 at 06:59 am EST - Marketscreener.com
JPMorgan cuts Bausch & Lomb stock price target to $17 - Investing.com
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Increases By 37.3% - MarketBeat
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Bloomberg
Contact lens maker Bausch + Lomb rules out going private at this time - Reuters
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal - Yahoo Canada Finance
Bausch + Lomb Provides Update on Potential Sale - Business Wire
B%26L+declines+offer+to+go+private%2C+continues+to+explore+sale+options - Rochester Business Journal
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
Bausch Health Q4 Results to Focus on 2025 Outlook, Potential Full Separation of Bausch + Lomb, RBC Says - Marketscreener.com
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Bausch Lomb Corporation (BLCO-T) QuotePress Release - The Globe and Mail
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Business Wire
This Bausch + Lomb Insider Increased Their Holding In The Last Year - Yahoo Finance
Ellsworth Advisors LLC Invests $665,000 in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wells Fargo & Company Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $24.00 - Defense World
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):